Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme

Results of North Central Cancer Treatment Group protocol N0177

Sunil Krishnan, Paul D. Brown, Karla V. Ballman, John B. Fiveash, Joon H. Uhm, Caterina Giannini, Kurt Jaeckle, Francois J. Geoffroy, L. Burt Nabors, Jan C. Buckner

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Purpose: To evaluate the toxicity and maximum tolerated dose (MTD) of erlotinib plus radiation therapy (RT) in patients with glioblastoma multiforme (GBM) in a multicenter phase I trial. Methods and Materials: Patients were stratified on the basis of the use of enzyme-inducing anticonvulsants (EIACs). After resection or biopsy, patients were treated with erlotinib for 1 week before concurrent erlotinib and 6 weeks (60 Gy) of RT and maintained on erlotinib until progression. The erlotinib dose was escalated in cohorts of 3 starting at 100 mg/day. Results: Twenty patients were enrolled and 19 were evaluable for the MTD and efficacy endpoints. Of these patients, 14 were males and 5 were females, with a median age of 54 years. Seven had undergone biopsy only, 5 had subtotal resections, and 7 had gross total resections. The highest dose level was 150 mg/day erlotinib for patients not on EIACs (Group 1) and 200 mg/day for patients on EIACs (Group 2). MTD was not reached in either group. In Group 1 at 100 mg (n = 6) and at 150 mg (n = 4), only 1 dose-limiting toxicity (DLT) occurred (stomatitis at 100 mg). No DLTs have occurred in Group 2 at 100 mg (n = 3), 150 mg (n = 3), and 200 mg (n = 3). With a median follow-up of 52 weeks, progression was documented in 16 patients and 13 deaths occurred. Median time to progression was 26 weeks, and median survival was 55 weeks. Conclusion: Toxicity is acceptable at the current doses of erlotinib plus RT. The study was modified to include concurrent and adjuvant temozolomide, and accrual is in progress.

Original languageEnglish (US)
Pages (from-to)1192-1199
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume65
Issue number4
DOIs
StatePublished - Jul 15 2006

Fingerprint

Antineoplastic Protocols
Glioblastoma
radiation therapy
Radiotherapy
cancer
anticonvulsants
dosage
Maximum Tolerated Dose
progressions
toxicity
Anticonvulsants
enzymes
temozolomide
Enzymes
Biopsy
Radiation Dosage
Stomatitis
Erlotinib Hydrochloride
death

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Krishnan, Sunil ; Brown, Paul D. ; Ballman, Karla V. ; Fiveash, John B. ; Uhm, Joon H. ; Giannini, Caterina ; Jaeckle, Kurt ; Geoffroy, Francois J. ; Nabors, L. Burt ; Buckner, Jan C. / Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme : Results of North Central Cancer Treatment Group protocol N0177. In: International Journal of Radiation Oncology Biology Physics. 2006 ; Vol. 65, No. 4. pp. 1192-1199.
@article{993c34aea83144a58c84d3a1e4c57ff4,
title = "Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: Results of North Central Cancer Treatment Group protocol N0177",
abstract = "Purpose: To evaluate the toxicity and maximum tolerated dose (MTD) of erlotinib plus radiation therapy (RT) in patients with glioblastoma multiforme (GBM) in a multicenter phase I trial. Methods and Materials: Patients were stratified on the basis of the use of enzyme-inducing anticonvulsants (EIACs). After resection or biopsy, patients were treated with erlotinib for 1 week before concurrent erlotinib and 6 weeks (60 Gy) of RT and maintained on erlotinib until progression. The erlotinib dose was escalated in cohorts of 3 starting at 100 mg/day. Results: Twenty patients were enrolled and 19 were evaluable for the MTD and efficacy endpoints. Of these patients, 14 were males and 5 were females, with a median age of 54 years. Seven had undergone biopsy only, 5 had subtotal resections, and 7 had gross total resections. The highest dose level was 150 mg/day erlotinib for patients not on EIACs (Group 1) and 200 mg/day for patients on EIACs (Group 2). MTD was not reached in either group. In Group 1 at 100 mg (n = 6) and at 150 mg (n = 4), only 1 dose-limiting toxicity (DLT) occurred (stomatitis at 100 mg). No DLTs have occurred in Group 2 at 100 mg (n = 3), 150 mg (n = 3), and 200 mg (n = 3). With a median follow-up of 52 weeks, progression was documented in 16 patients and 13 deaths occurred. Median time to progression was 26 weeks, and median survival was 55 weeks. Conclusion: Toxicity is acceptable at the current doses of erlotinib plus RT. The study was modified to include concurrent and adjuvant temozolomide, and accrual is in progress.",
author = "Sunil Krishnan and Brown, {Paul D.} and Ballman, {Karla V.} and Fiveash, {John B.} and Uhm, {Joon H.} and Caterina Giannini and Kurt Jaeckle and Geoffroy, {Francois J.} and Nabors, {L. Burt} and Buckner, {Jan C.}",
year = "2006",
month = "7",
day = "15",
doi = "10.1016/j.ijrobp.2006.01.018",
language = "English (US)",
volume = "65",
pages = "1192--1199",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme : Results of North Central Cancer Treatment Group protocol N0177. / Krishnan, Sunil; Brown, Paul D.; Ballman, Karla V.; Fiveash, John B.; Uhm, Joon H.; Giannini, Caterina; Jaeckle, Kurt; Geoffroy, Francois J.; Nabors, L. Burt; Buckner, Jan C.

In: International Journal of Radiation Oncology Biology Physics, Vol. 65, No. 4, 15.07.2006, p. 1192-1199.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme

T2 - Results of North Central Cancer Treatment Group protocol N0177

AU - Krishnan, Sunil

AU - Brown, Paul D.

AU - Ballman, Karla V.

AU - Fiveash, John B.

AU - Uhm, Joon H.

AU - Giannini, Caterina

AU - Jaeckle, Kurt

AU - Geoffroy, Francois J.

AU - Nabors, L. Burt

AU - Buckner, Jan C.

PY - 2006/7/15

Y1 - 2006/7/15

N2 - Purpose: To evaluate the toxicity and maximum tolerated dose (MTD) of erlotinib plus radiation therapy (RT) in patients with glioblastoma multiforme (GBM) in a multicenter phase I trial. Methods and Materials: Patients were stratified on the basis of the use of enzyme-inducing anticonvulsants (EIACs). After resection or biopsy, patients were treated with erlotinib for 1 week before concurrent erlotinib and 6 weeks (60 Gy) of RT and maintained on erlotinib until progression. The erlotinib dose was escalated in cohorts of 3 starting at 100 mg/day. Results: Twenty patients were enrolled and 19 were evaluable for the MTD and efficacy endpoints. Of these patients, 14 were males and 5 were females, with a median age of 54 years. Seven had undergone biopsy only, 5 had subtotal resections, and 7 had gross total resections. The highest dose level was 150 mg/day erlotinib for patients not on EIACs (Group 1) and 200 mg/day for patients on EIACs (Group 2). MTD was not reached in either group. In Group 1 at 100 mg (n = 6) and at 150 mg (n = 4), only 1 dose-limiting toxicity (DLT) occurred (stomatitis at 100 mg). No DLTs have occurred in Group 2 at 100 mg (n = 3), 150 mg (n = 3), and 200 mg (n = 3). With a median follow-up of 52 weeks, progression was documented in 16 patients and 13 deaths occurred. Median time to progression was 26 weeks, and median survival was 55 weeks. Conclusion: Toxicity is acceptable at the current doses of erlotinib plus RT. The study was modified to include concurrent and adjuvant temozolomide, and accrual is in progress.

AB - Purpose: To evaluate the toxicity and maximum tolerated dose (MTD) of erlotinib plus radiation therapy (RT) in patients with glioblastoma multiforme (GBM) in a multicenter phase I trial. Methods and Materials: Patients were stratified on the basis of the use of enzyme-inducing anticonvulsants (EIACs). After resection or biopsy, patients were treated with erlotinib for 1 week before concurrent erlotinib and 6 weeks (60 Gy) of RT and maintained on erlotinib until progression. The erlotinib dose was escalated in cohorts of 3 starting at 100 mg/day. Results: Twenty patients were enrolled and 19 were evaluable for the MTD and efficacy endpoints. Of these patients, 14 were males and 5 were females, with a median age of 54 years. Seven had undergone biopsy only, 5 had subtotal resections, and 7 had gross total resections. The highest dose level was 150 mg/day erlotinib for patients not on EIACs (Group 1) and 200 mg/day for patients on EIACs (Group 2). MTD was not reached in either group. In Group 1 at 100 mg (n = 6) and at 150 mg (n = 4), only 1 dose-limiting toxicity (DLT) occurred (stomatitis at 100 mg). No DLTs have occurred in Group 2 at 100 mg (n = 3), 150 mg (n = 3), and 200 mg (n = 3). With a median follow-up of 52 weeks, progression was documented in 16 patients and 13 deaths occurred. Median time to progression was 26 weeks, and median survival was 55 weeks. Conclusion: Toxicity is acceptable at the current doses of erlotinib plus RT. The study was modified to include concurrent and adjuvant temozolomide, and accrual is in progress.

UR - http://www.scopus.com/inward/record.url?scp=33745183568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745183568&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2006.01.018

DO - 10.1016/j.ijrobp.2006.01.018

M3 - Article

VL - 65

SP - 1192

EP - 1199

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -